Rosenblatt Securities upgraded shares of Bradmer Pharmaceuticals (TSE:GLX – Free Report) to a strong-buy rating in a research report report published on Tuesday,Zacks.com reports.
Other equities analysts also recently issued research reports about the company. BTIG Research upgraded Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Monday, April 14th. Benchmark upgraded Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Monday, March 31st. Finally, Cantor Fitzgerald raised Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, February 25th. Five analysts have rated the stock with a strong buy rating, According to data from MarketBeat, Bradmer Pharmaceuticals has a consensus rating of “Strong Buy”.
Read Our Latest Stock Analysis on GLX
Bradmer Pharmaceuticals Stock Performance
Featured Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- How to Calculate Stock Profit
- Astera Labs: AI Infrastructure Play With Significant Growth Ahead
- How to Short a Stock in 5 Easy Steps
- Is IBM’s AI Transformation Powering a Sustained Rally?
- Stock Sentiment Analysis: How it Works
- NVIDIA’s Stock Price Hits New Highs: This Is What’s Next
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.